Envisagenics
PrivateLast Round
Series B
Jun 5, 2024
Total Funding Raised
$50.56M
Company Overview
Envisagenics is a biotechnology company that develops an AI-driven bioinformatics platform to accelerate the discovery and validation of novel RNA splicing-based drug targets for oncology and neurodegenerative diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Medical AI
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Envisagenics Comparables
Compare Envisagenics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Deep Genomics | 85% | |
| Panorama Medicine | 84% | |
| Anima Biotech | 81% | |
Envisagenics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Jun 5, 2024 | ||||
| Grant | Aug 2, 2022 | ||||
| Series A | Sep 29, 2021 | ||||
| Grant | Oct 23, 2019 | ||||
| Grant | May 22, 2018 | ||||
Seed | Nov 28, 2017 |
Key People
Founding team and executive leadership
Envisagenics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| National Cancer Institute | Grant |
| Dynamk Capital | Series A, Seed |
| SV Angel | Seed |
| Dolby Family Ventures | Seed |
| NIH RADx | Grant |
| Jove Equity Partners | Grant |
| M12 - Microsoft's Venture Fund | Grant, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Feb 13, 2025
Sudhir Rao appointed as new Chief Business Officer.
- Jun 5, 2024
$25M round led by Third Kind Venture Capital and Celgene.
Envisagenics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Envisagenics's valuation, stock price, and market status.